<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34730287</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Influenza and other respiratory viruses</Title><ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation></Journal><ArticleTitle>Occurrence and disease burden of respiratory syncytial virus and other respiratory pathogens in adults aged ≥65 years in community: A prospective cohort study in Japan.</ArticleTitle><Pagination><StartPage>298</StartPage><EndPage>307</EndPage><MedlinePgn>298-307</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.12928</ELocationID><Abstract><AbstractText Label="BACKGROUND">The frequency and clinical profile of respiratory syncytial virus (RSV)-acute respiratory disease (ARD) in older adults in Japan has not been well-characterized.</AbstractText><AbstractText Label="METHODS">This was a multicenter prospective observational cohort study to evaluate the occurrence rate of ARD in 1000 older adult participants (≥65 years) for 52 weeks during the 2019 to 2020 season. A multiplex polymerase chain reaction panel was used for pathogen detection in nasopharyngeal swab from participants diagnosed with ARD. Symptoms and impact of ARD was assessed using the Respiratory Infection Intensity and Impact Questionnaire (RiiQ™). The study was registered at UMIN (https://www.umin.ac.jp/ctr/): UMIN000037891.</AbstractText><AbstractText Label="RESULTS">RSV-ARD was detected in 24/1000 (2.4%) participants and RSV-lower respiratory tract disease in 8/1000 (0.8%) participants. The median duration of RSV-ARD was 18 days. All 24 participants had utilized the medical services of outpatient visits and only 1 (4.2%) participant was hospitalized for RSV-ARD. The most common viruses other than RSV that caused ARD (detected in &gt;10 participants) were human rhinovirus/enterovirus, parainfluenza 3, coronavirus OC43, human metapneumovirus, and influenza A/H1. The most frequent symptoms of RSV-ARD were cough, sore throat, nasal congestion, and expectoration.</AbstractText><AbstractText Label="CONCLUSIONS">RSV was reported as a major pathogen for respiratory infections in older adults in Japan.</AbstractText><CopyrightInformation>© 2021 Janssen Pharmaceutical K.K. Influenza and Other Respiratory Viruses published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kurai</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9492-8798</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Kyorin University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natori</LastName><ForeName>Makiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research and Development Division, Janssen Pharmaceutical K. K, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Maho</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research and Development Division, Janssen Pharmaceutical K. K, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Richuan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Research and Development Division, Janssen Pharmaceutical K. K, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Research and Development Division, Janssen Pharmaceutical K. K, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Saka General Hospital, Miyagi, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Janssen Pharmaceutical K.K</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Influenza Other Respir Viruses</MedlineTA><NlmUniqueID>101304007</NlmUniqueID><ISSNLinking>1750-2640</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029121" MajorTopicYN="Y">Metapneumovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018357" MajorTopicYN="Y">Respiratory Syncytial Virus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018113" MajorTopicYN="Y">Respiratory Syncytial Virus, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Japanese older adults</Keyword><Keyword MajorTopicYN="N">acute respiratory disease</Keyword><Keyword MajorTopicYN="N">community</Keyword><Keyword MajorTopicYN="N">respiratory infection intensity questionnaire (RiiQ™)</Keyword><Keyword MajorTopicYN="N">respiratory pathogens</Keyword><Keyword MajorTopicYN="N">respiratory syncytial virus</Keyword></KeywordList><CoiStatement>Potential conflict of interest: NM, YM, ZR, and SY are full time employees and KD had been a consultant of Janssen Pharmaceutical K.K., Tokyo, Japan. NM and YM are J&amp;J stockholders. No conflict of interest: TH reports no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>8</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34730287</ArticleId><ArticleId IdType="pmc">PMC8818832</ArticleId><ArticleId IdType="doi">10.1111/irv.12928</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Centers for Disease Control and Prevention
. Respiratory syncytial virus infection (RSV). Available at: https://www.cdc.gov/rsv/index.html. Accessed 08 April 2021.</Citation></Reference><Reference><Citation>Shi T, Denouel A, Tietjen AK, et al. Global disease burden estimates of respiratory syncytial virus‐associated acute respiratory infection in older adults in 2015: a systematic review and meta‐analysis. J Infect Dis. 2020;222(supplement_7:S577‐S583.</Citation><ArticleIdList><ArticleId IdType="pubmed">30880339</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946‐985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5592248</ArticleId><ArticleId IdType="pubmed">28689664</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high‐risk adults. N Engl J Med. 2005;352(17):1749‐1759.</Citation><ArticleIdList><ArticleId IdType="pubmed">15858184</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsten K, Adriaenssens N, Coenen S, et al. Burden of respiratory syncytial virus infection in community‐dwelling older adults in Europe (RESCEU): an international prospective cohort study. Eur Respir J. 2021;57(4):2002688.</Citation><ArticleIdList><ArticleId IdType="pubmed">33060153</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000;13(3):371‐384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88938</ArticleId><ArticleId IdType="pubmed">10885982</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Institute of Infectious Diseases, Japan [homepage on the Internet] (NIID
. 2018) Current status of RS virus vaccine development and global surveillance. Available at https://www.niid.go.jp/niid/ja/typhi-m/iasr-reference/2437-related-articles/related-articles-466/8484-466r08.html. Accessed 15 April 2021.</Citation></Reference><Reference><Citation>
Ministry of Internal Affairs and Communication [homepage on the Internet]
. Available at: http://www.stat.go.jp/data/jinsui/pdf/201806.pdf. Accessed 15 April 2021.</Citation></Reference><Reference><Citation>
National Institute of Infectious Diseases, Japan [homepage on the Internet] (NIID
. 2018). Available at: https://www.niid.go.jp/niid/ja/10/2096-weeklygraph/1661-21rsv.html. Accessed 12 April 2021.</Citation></Reference><Reference><Citation>Fleming DM, Taylor RJ, Lustig RL, et al. Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis. 2015;15(1):443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4618996</ArticleId><ArticleId IdType="pubmed">26497750</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne RH, Norquist JM, Mehta V, et al. Development and validation of the intensity and impact of influenza questionnaire (Flu‐iiQ). Value Health. 2011;14(5):687‐699.</Citation><ArticleIdList><ArticleId IdType="pubmed">21839407</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne RH, Nelson L, Elsworth GR, et al. Psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire Version 2 (RiiQ™) symptom scores for respiratory syncytial virus. Poster presented at the Virtual ISPOR Conference. Vol. 24; 2021:S119.</Citation></Reference><Reference><Citation>Collin C. (1988), Wade DT, Davies S, Horne V. The Barthel ADL Index: a reliability study. Int Disabil Stud. 1988;10(2):61‐63.</Citation><ArticleIdList><ArticleId IdType="pubmed">3403500</ArticleId></ArticleIdList></Reference><Reference><Citation>Murcia J, Llorens P, Sánchez‐Payá J, et al. Functional status determined by Barthel Index predicts community acquired pneumonia mortality in general population. J Infect. 2010;61(6):458‐464.</Citation><ArticleIdList><ArticleId IdType="pubmed">20797406</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulc E, Pallauf M, Mueller G, Wildbahner T, Them C. Is the Barthel Index an adequate assessment tool for identifying a risk group in elderly people living at home? Int J Nurs Clin Pract. 2015;2015(2):140.</Citation></Reference><Reference><Citation>Falsey AR, McElhaney JE, Beran J, et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza‐like illness. J Infect Dis. 2014;209(12):1873‐1881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038137</ArticleId><ArticleId IdType="pubmed">24482398</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos LM, Bruyndonckx R, Zuithoff NPA, et al. Lower respiratory tract infection in the community: associations between viral aetiology and illness course. Clin Microbiol Infect. 2021;27(1):96‐104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118666</ArticleId><ArticleId IdType="pubmed">32244051</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis. 2004;189(2):233‐238.</Citation><ArticleIdList><ArticleId IdType="pubmed">14722887</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta J, Walsh EE, Mahadevia PJ, Falsey AR. Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease. COPD. 2013;10(3):293‐299.</Citation><ArticleIdList><ArticleId IdType="pubmed">23536980</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin MR, Coffey CS, Neuzil KM, Mitchel EF Jr, Wright PF, Edwards KM. Winter viruses: influenza‐ and respiratory syncytial virus‐related morbidity in chronic lung disease. Arch Intern Med. 2002;162(11):1229‐1236.</Citation><ArticleIdList><ArticleId IdType="pubmed">12038940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerson B, Tseng HF, Sy LS, et al. Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults. Clin Infect Dis. 2019;69(2):197‐203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6603263</ArticleId><ArticleId IdType="pubmed">30452608</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>